Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

BACKGROUND: Advanced renal cell carcinoma (RCC) has a very dismal prognosis. Cabozantinib, a tyrosine kinase inhibitor, has been approved for the treatment of advanced RCC. However, the impact of cabozantinib on the immune microenvironment of RCC remains poorly understood. METHODS: Kaplan-Meier surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongyan, Sun, Shishuo, Wang, Gang, Lu, Mengmeng, Zhang, Xiaokang, Wei, Xiaohuan, Gao, Xiaoge, Huang, Chao, Li, Zhen, Zheng, Junnian, Zhang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089383/
https://www.ncbi.nlm.nih.gov/pubmed/33954115
http://dx.doi.org/10.3389/fonc.2021.663517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089383/
https://www.ncbi.nlm.nih.gov/pubmed/33954115
http://dx.doi.org/10.3389/fonc.2021.663517

Ejemplares similares